Finerenone in IgA nephropathy: real-world 12-month propensity-matched cohort demonstrating proteinuria reduction, eGFR preservation, and safety profile

Objective To evaluate the efficacy and safety of finerenone in patients with IgA nephropathy (IgAN).Methods This retrospective study included 105 patients with IgAN (35 in the finerenone group, 70 in the control group) from January 2022 to February 2025. The finerenone group received conventional th...

Description complète

Détails bibliographiques

Auteurs principaux:	Wei Zhang, Jing-ting Yu, Bo Lin, Xiaogang Shen, Maosheng Chen, Yi-dong Zhou, Yu-jia Zhang, Cheng-cong Zhuo, Zhi-liang Jiang, Bin Zhu
Format:	Artigo
Langue:	Inglês
Publié:	Taylor & Francis Group 2026-12-01
Collection:	Renal Failure
Sujets:	IgA nephropathy finerenone non-steroidal mineralocorticoid receptor antagonist (MRA) proteinuria eGFR decline real-world evidence
Accès en ligne:	https://www.tandfonline.com/doi/10.1080/0886022X.2026.2644719
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!